Pharmaceutical
Technology
Health

Osiris Therapeutics

$19.01
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.01 (-0.05%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell OSIR and other stocks, options, ETFs, and crypto commission-free!

About

Osiris Therapeutics, Inc. engages in researching, developing, manufacturing and commercializing regenerative medicine products. It operates through Biosurgery segment which focuses on using unique tissue preservation technologies to develop viable human tissue products designed to improve wound closure and surgical outcomes for patients and physicians over standard of care alone. Read More The company was founded by Peter A. Friedli and James S. Burns on December 23, 1992 and is headquartered in Columbia, MD.

Employees
342
Headquarters
Columbia, Maryland
Founded
1992
Market Cap
656.70M
Price-Earnings Ratio
17.81
Dividend Yield
0.00
Average Volume
86.02K
High Today
$19.14
Low Today
$19.00
Open Price
$19.06
Volume
62.25K
52 Week High
$19.30
52 Week Low
$7.01

Collections

Pharmaceutical
Technology
Health
Therapy
Research And Development
Medical
US
North America

News

StreetInsiderMar 20

Form SC TO-T OSIRIS THERAPEUTICS, Filed by: SMITH & NEPHEW PLC

-- Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OSIRIS THERAPEUTICS, INC. (Name of Subject Company) PAPYRUS ACQUISITION CORP. (Offeror) SMITH & NEPHEW CONSOLIDATED, INC. SMITH & NEPHEW PLC (Parent of Offeror) (Names of Filing Persons) Common stock, par value $0.001 per share (Title of...

38
Yahoo FinanceMar 15

SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Osiris Therapeutics, Inc. – OSIR

BALA CYNWYD, PA / ACCESSWIRE / March 15, 2019 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Osiris Therapeutics, Inc.

47
Markets InsiderMar 15

SHAREHOLDER ALERT: WeissLaw LLP Investigates Osiris Therapeutics, Inc.

NEW YORK, March 15, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Osiris Therapeutics, Inc.

12

Earnings

Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
Expected Mar 27, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.